Evidence map›Paper›PMID 41432753›Full record

SynthesisAnnals of hematology2025

The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Chengxin Luo, Jianmin Zhang, Xiangtao Huang, Guixian Wu, Yarui Huang, Yaqun Ding, Zhen Huang, Qiuyue Song, Jieping Chen, Xi Li and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chengxin Luo *Center for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Jianmin Zhang *Center for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Xiangtao HuangCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Guixian WuCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Yarui HuangCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Yaqun DingCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Zhen HuangCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Qiuyue SongDepartment of Health Statistics, Third Military Medical University, Chongqing, China.
Jieping ChenCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Xi LiDepartment of Hematology, Daping Hospital, Third Military Medical University, No. 10 Chang-Jiang Brunch Road, Yuzhong district, Chongqing, 400042, China. lixi1988xn@163.com.
Shuangnian XuCenter for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China. xushuangnian@tmmu.edu.cn.

Funding

National Natural Science Foundation of China NSFC82000169Natural Science Foundation of Chongqing cstc2020jcyj-msxmX1058
6 · The paper itself

Abstract

Decitabine shows favorable efficacy in induction and maintenance therapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but its role in pre-transplant conditioning still has not been established. We performed a systematic review and meta-analysis of comparative studies investigating the effects of adding decitabine to conditioning regimens in AML/MDS patients undergoing allogeneic hematopoietic stem cell transplantation. Meta-analysis was conducted with Review Manager 5.4. For time-to-event outcomes, pooled hazard ratios (HRs) were calculated using generic inverse-variance method. For dichotomous data, pooled risk ratios (RRs) were calculated using Mantel-Haenszel method. Fixed-effects model was adopted if there is no significant heterogeneity. Literature search and study selection identify 9 eligible studies, including 2 randomized controlled trials and 7 retrospective comparative studies. Meta-analysis show that addition of decitabine to conditioning regimen is associated with significantly better overall survival (HR 0.61; 95% CI: 0.49-0.76; P < 0.00001), reduced risk of relapse (HR 0.58; 95% CI: 0.46-0.73; P < 0.00001), and better disease-free survival (HR 0.67; 95% CI: 0.55-0.81; P < 0.0001) without increasing non-relapse mortality (HR 0.82; 95% CI: 0.56-1.18; P = 0.28) and grade II-IV acute graft-versus-host disease (RR 0.75; 95% CI: 0.54-1.04; P = 0.08).

Indexed as

Antimetabolites, AntineoplasticDecitabineHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesTransplantation ConditioningHumansTransplantation, HomologousAntimetabolites, AntineoplasticDecitabineAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationConditioningDecitabineMyelodysplastic syndrome

Identifiers

PMID41432753
PMCPMC12764698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.